autpaxautbellum
28 Apr 2017
Re: Could our little machine Agree nice - I think that it is known that Parsortix can indicate whether the drugs are working or the dose may be altered to suit the patient.However, the BBC (I haven't read the actual report) seem to be having a pop at Cameron and the Torys: there was outcry over drugs that people thought could help them, not being available on the NHS and he attempted to make it happen.
niceandsimple
28 Apr 2017
Could our little machine have helped? Get the impression it wasn't with whats been said on the radio - may be wrong on this.[link] budgets under constraints surely our time will come for targeted medicine interventionThe Cancer Drugs Fund should be kept going but with our machine confirming medicinal efficacyN&S
claude reins
05 Apr 2017
Re: Q2 2017 trigger? Fair point.
millwallfan
05 Apr 2017
Re: Q2 2017 trigger? But there were under 27m shares in issue in 2010 so well more than double that now so you need to compare apples with apples not with grapes.
claude reins
04 Apr 2017
Re: Q2 2017 trigger? Hi BPlate. Thanks for that. Tempted to add to holding on 2 fronts. The performance and spread of performance is so strong that it seems inevitable it will be adopted soon. Secondly, as you say if it is so good, then it will be a tasty buy for some of the bigger boys. I dont know who they are, but they will!To think it came tlo the market in 2004, March, at 144p and peaked a year later at 166p. Amazing how the performance can only now be at a peak and the shares close to their 3 year low - 100p around the same time 3 years ago. Must be a strong hold at least, and tempted to go in for more.
Broken Plate
03 Apr 2017
Re: Q2 2017 trigger? The academics can praise it from their labs as the best thing since sliced bread and get their doctorates doing it but until Parsortix becomes the standard to use in diagnosis there will be no sales/income and I suspect protectionism from existing products who have a vested interest to promote their outdated products rather than let AGL grab some of that action.In every test we know of Parsortix has outperformed its rivals and even I am beginning to ask why it hasn't been snapped up by the competition when it obviously works and does what it says on the packet.Money is the key and who has it - not whether the product is superior or save lives.At the time of writing 506,000 bought and 15000 sold makes me wonder if the sp is being held back to fulfill these large orders - this is aim at it's best.
claude reins
03 Apr 2017
Re: Q2 2017 trigger? I am 40% down on the time when I bought these on the basis of the breast cancer promise. Since then, that has been backed up by ovarian cancer, prostate cancer and now head and neck cancer. How mmuch do they have to prove their potential, and why has the price fallen so far rather than the reverse? Yes, it is some time off before they make the promised money, but how many stocks does that apply to and without the promise of Angle?Any logical explanation gratefully reeived.PS fortunately I didnt buy that many, but would like to buy more!
claude reins
03 Apr 2017
Re: Head and neck cancer test Yes how much more god news can qwe take before the SP takes off. This is a huge competitive opportunity, 600,000 cases a year of head and neck cancer, yet the market seems to ignore it! It should be a strong buy, given the road ranging good news, but how many cancers does it have to prove it is effective for to get some SP recognitition. ANGLE plc ("the Company"
PARSORTIX ENABLES GENE EXPRESSION ANALYSIS IN HEAD AND NECK CANCER Customer presents clinically relevant results at AACR 2017 with Parsortix where alternative approaches have failed University of Athens, Attikon University Hospital, Greece first to demonstrate use of the Parsortix system in head and neck cancer ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that the University of Athens and Attikon University Hospital, Greece are today presenting highly encouraging results from their work with ANGLE's Parsortix system in head and neck squamous cell carcinomas at the American Association for Cancer Research conference (AACR) 2017, in Washington DC. The results show that in a study of 40 cancer patients, the Parsortix system demonstrated higher sensitivity and greater purity in harvesting CTCs for analysis than leading alternative approaches. Information regarding the expression of key genes (including PD-L1 and CK-19) could be determined from simple blood samples taken from each patient. In parallel, identical samples from each patient were assessed using antibody-based (EpCAM-dependent) approaches. These approaches failed to detect PD-L1 or CK-19 in any of the 40 samples. The University of Athens work suggest that, for the first time, it might be possible to assess gene expression of head and neck cancers using a Parsortix non-invasive liquid biopsy. Gene expression of biomarkers such as PD-L1 provides key information regarding likely patient response to immunotherapies and has the potential to be of significant clinical importance for the therapy selection and follow-up of patients. Head and neck cancer is the sixth most common cancer worldwide with over 600,000 new patients diagnosed annually resulting in more than 350,000 deaths every year. More than 90% of head and neck cancers are squamous cell carcinomas (HNSCC) which account for 5-10% of all new cancer cases in Europe and North America. Head and neck cancer represents a new market opportunity for Parsortix as other liquid biopsy approaches have been unsuccessful in this indication: gene expression analysis cannot be achieved with antibody-based CTC systems due to low expression of EpCAM and cannot be achieved using alternative ctDNA approaches as it is based on RNA. Prof Evi Lianidou, Head of the Molecular Diagnostics Laboratory focused on Liquid Biopsy, University of Athens, commented:"The low EpCAM expression in head and neck cancer has previously prevented us from liquid biopsy analysis. The Parsortix system's epitope independence, high sensitivity and purity now makes this possible. Our results show excellent RNA quality and the potential to analyse a simple blood test to provide key gene expression information." ANGLE Founder and Chief Executive, Andrew Newland, commented:"The advantages of the Parsortix system, in head and neck cancer, over the existing antibody-based approaches increases the market opportunity available to ANGLE. The University of Athens is a leader in CTC research and the successful completion of this work by a customer validates a key element of our roll-out strategy of using research-use sales to drive the development of clinical applications for the Parsortix system."
autpaxautbellum
03 Apr 2017
Head and neck cancer test Another area showing Parsortix' versatility.
niceandsimple
02 Apr 2017
A little read possibly to calm the old nerves[link]
niceandsimple
30 Mar 2017
Q2 2017 trigger? POSITIVE INTERIM EVALUATION OF OVARIAN CANCER CLINICAL STUDIES Patient enrolment European study now over 90% complete and US study 70% complete Headline data from the full studies expected in Q2, 2017Guess I'll just wait like the rest of us and hopeN&S
niceandsimple
30 Mar 2017
Another RNSClearly not the RNS Clearly not the RNS the market is waiting for. The market I feel acknowledges / knows the product works and apathy currently rules. Who knows if there is more drift downwards until we obtain the anticipated commercialisation deals that will ignite the sp.First impressions - I actually thought AN was not his usual upbeat self but what more can he say that's not been said already?More needs to be said about how successful our product is integrating with the mass machines in anticipation of commercialisationN&S
Good money after bad
17 Feb 2017
Up 16% this week No news.Someone must be in the know ?!
Good money after bad
15 Feb 2017
Rise Nice rise today....hopefully someone knows something !
millwallfan
02 Feb 2017
Re: Presentation from 31-Jan-17 Forum Let's hope for a much better reaction in days to come once this has been digested than we have seen today. With FDA approval likely within 12 months this surely cannot remain depressed much longer. Look at what happened to GWP one USA was on board -it rose something like sixfold from memory !!
